5PSQ-014 Prescribing accuracy of the direct oral anticoagulants in a tertiary university hospital

Onderzoeksoutput: Unpublished paper


Background The introduction of the direct oral anticoagulants (DOACs) widened the options for anticoagulation in atrial fibrillation (AF) and venous thromboembolism. Although they have made anticoagulation more convenient, caution is warranted in patients with renal impairment to decrease bleeding risk as they are partly renally cleared. Purpose The purpose of this study was to determine the prescribing accuracy of dabigatran etexilate, rivaroxaban and apixaban according to the summaries of product characteristics. Second, bleeding complications or thromboembolic events following inappropriate dosing were investigated. A high rate of dosing errors could lead us to develop clinical decision support systems to prevent such errors. Material and methods Single-centre, retrospective cohort study conducted in patients≥60 years admitted to UZ Brussel (721- bed university hospital) in 2016 with at least one intake of dabigatran etexilate, rivaroxaban or apixaban. Renal function was estimated using three formulas (Cockcroft-Gault, MDRD and CKD-EPI). Prescribers were divided into interns and noninterns. Statistical differences between groups were evaluated using ANOVA and the Chi Square test. Results A total of 998 admissions for 777 patients were consequently included. The median CrCl for dabigatran, rivaroxaban and apixaban users was respectively 58, 59 and 54 mL/ min: the median eGFR 65.5; 65 and 59 mL/min/1.73 m2 (CKD-EPI) (p
Originele taal-2English
StatusPublished - mrt 2018


Duik in de onderzoeksthema's van '5PSQ-014 Prescribing accuracy of the direct oral anticoagulants in a tertiary university hospital'. Samen vormen ze een unieke vingerafdruk.

Citeer dit